Bekir Ucan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bekir Ucan has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Erman Cakal
Department of Endocrinology and Metabolism, Ankara Etlik City Hospital, Ankara, Türkiye
9 shared publications - Melia Karakose
Diskapi Yildirim Beyazit Training and Research Hospital, Turkey
8 shared publications - Mustafa Ozbek
Department of Endocrinology and Metabolism, Ankara Etlik City Hospital, Ankara, Türkiye
8 shared publications Tuncay Delibasi
7 shared publicationsMuyesser Sayki Arslan
6 shared publicationsEsra Tutal
5 shared publications
Latest Publications
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
The diagnostic value of elastography score and strain indexfor the evaluation of thyroid micronodules
Background and aim: In the general population, the frequency of thyroid micronodules is increasing and the prevalence of malignancy is higher in nodules at this size. The ultrasonographic features of these nodules are neither spesific nor sensitive Elastography gives information about the degree of hardness at the tissue level and provides assessment of malignancy risk of the nodule. The aim of the study was to investigate the diagnostic value of elastography in patients with thyroid micronodules. Methods: Two hundred and twenty-four patients with thyroid micronodules were recruited in this prospective study. All patients underwent a thyroid fine-needle aspiration biopsy (FNAB). Elastography scores and indexes were measured with real-time ultrasound elastography (Preirus HV machine with 13 MHz linear transducer). Results: The outcome of our study shows that malignant micronodules compared the bening micronodules, malignant micronodules were with higher elastography scores (ES) and strain indexes (SI) values (P3 providing 79.4% sensitivity and 98.1% specificity for diagnosing malignancy. The area under the curve (AUC) for the ES was 0.888 (P< 0.001). The best cut-off point for strain index which differentiates benign from malignant micronodules was 3.06 with 98% sensitivity, 91% specificity. AUC for the SI was 0.970 (P<0.001). Conclusions: Elastography score and strain ratio of the thyroid micronodules are beneficial markers during malignancy investigation. According to our study, the strain index is better than elasto score when assessing the malignancy in thyroid micronodules.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
The diagnostic value of elastography score and strain indexfor the evaluation of thyroid micronodules
Background and aim: In the general population, the frequency of thyroid micronodules is increasing and the prevalence of malignancy is higher in nodules at this size. The ultrasonographic features of these nodules are neither spesific nor sensitive Elastography gives information about the degree of hardness at the tissue level and provides assessment of malignancy risk of the nodule. The aim of the study was to investigate the diagnostic value of elastography in patients with thyroid micronodules. Methods: Two hundred and twenty-four patients with thyroid micronodules were recruited in this prospective study. All patients underwent a thyroid fine-needle aspiration biopsy (FNAB). Elastography scores and indexes were measured with real-time ultrasound elastography (Preirus HV machine with 13 MHz linear transducer). Results: The outcome of our study shows that malignant micronodules compared the bening micronodules, malignant micronodules were with higher elastography scores (ES) and strain indexes (SI) values (P3 providing 79.4% sensitivity and 98.1% specificity for diagnosing malignancy. The area under the curve (AUC) for the ES was 0.888 (P< 0.001). The best cut-off point for strain index which differentiates benign from malignant micronodules was 3.06 with 98% sensitivity, 91% specificity. AUC for the SI was 0.970 (P<0.001). Conclusions: Elastography score and strain ratio of the thyroid micronodules are beneficial markers during malignancy investigation. According to our study, the strain index is better than elasto score when assessing the malignancy in thyroid micronodules.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Somatostatin Analogue Treatment of a Persistant TSH-Secreting Adenoma: a report of case
Introduction: Thyrotropinomas are usually considered when the TSH level is inappropriately elevated or normal in a hyperthyroid patient with increased serum T4 levels, regardless of the presence of visible tumor on imaging. The prevalence of these adenomas, which account for 0.5–3% of all pituitary tumors has been estimated to be around one case per million. Most thyrotroph adenomas are large and invasive at diagnosis, and present with signs and symptoms of an expanding mass, including temporal visual field defects. Here, we report a patient treated with somatostatin analogue with pituitary macroadenoma and hyperthyroidism. Case reports: A 64-year-old female patient, who had undergone surgical procedure in 2014 for solitary fibrous tumor in the left parietal region, applied to be checked because of enlarged hypophysis gland documented via cranial MRI performed during follow-up visits. Laboratory findings revealed high levels of fT3 (8.56 pg/ml) and fT4 (2.1 ng/ml) with TSH (6.32 UI/ml) higher than its normal limit. On the MRI of the hypophysis, a 22×18×14 mm lesion consistent with macroadenoma, which was heterogeneously contrasted after IV Gad injection, was detected in the mid-left half of the pituitary gland. The lesion exceeds the lateral inter-carotid line in the left aspect and surrounds the left ICA higher than 240 degree. Other hormones of the anterior hypophysis were within the normal range. SHBG was 153.9 (30–100 nmol/l) and alpha subunit was 3.9 (0–1.6 IU/l), which were high. There was no response to TRH stimulation test. Methimazole was commenced at a dose of 20 mg and transnasal transsphenoidal pituitary adenomectomy was performed. Somatostatin analogue (Octreotid LAR 10 mg/28 day) therapy was started for the patient, who had residual adenoma (20×15 mm) and in whom euthyroidism could not be achieved. Methimazole was interrupted in the 9th month of somatostatin analogue treatment and determining that the size of adenoma is 10×9×8 mm. Conclusion: Most thyrotrophs express variable number of somatostatin receptors (SSTR), particularly SSTR2 and SSTR5. Somatostatin analogues could be considered in the treatment of persistent disease following the surgical procedure performed for TSH-secreting adenomas.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Somatostatin Analogue Treatment of a Persistant TSH-Secreting Adenoma: a report of case
Introduction: Thyrotropinomas are usually considered when the TSH level is inappropriately elevated or normal in a hyperthyroid patient with increased serum T4 levels, regardless of the presence of visible tumor on imaging. The prevalence of these adenomas, which account for 0.5–3% of all pituitary tumors has been estimated to be around one case per million. Most thyrotroph adenomas are large and invasive at diagnosis, and present with signs and symptoms of an expanding mass, including temporal visual field defects. Here, we report a patient treated with somatostatin analogue with pituitary macroadenoma and hyperthyroidism. Case reports: A 64-year-old female patient, who had undergone surgical procedure in 2014 for solitary fibrous tumor in the left parietal region, applied to be checked because of enlarged hypophysis gland documented via cranial MRI performed during follow-up visits. Laboratory findings revealed high levels of fT3 (8.56 pg/ml) and fT4 (2.1 ng/ml) with TSH (6.32 UI/ml) higher than its normal limit. On the MRI of the hypophysis, a 22×18×14 mm lesion consistent with macroadenoma, which was heterogeneously contrasted after IV Gad injection, was detected in the mid-left half of the pituitary gland. The lesion exceeds the lateral inter-carotid line in the left aspect and surrounds the left ICA higher than 240 degree. Other hormones of the anterior hypophysis were within the normal range. SHBG was 153.9 (30–100 nmol/l) and alpha subunit was 3.9 (0–1.6 IU/l), which were high. There was no response to TRH stimulation test. Methimazole was commenced at a dose of 20 mg and transnasal transsphenoidal pituitary adenomectomy was performed. Somatostatin analogue (Octreotid LAR 10 mg/28 day) therapy was started for the patient, who had residual adenoma (20×15 mm) and in whom euthyroidism could not be achieved. Methimazole was interrupted in the 9th month of somatostatin analogue treatment and determining that the size of adenoma is 10×9×8 mm. Conclusion: Most thyrotrophs express variable number of somatostatin receptors (SSTR), particularly SSTR2 and SSTR5. Somatostatin analogues could be considered in the treatment of persistent disease following the surgical procedure performed for TSH-secreting adenomas.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Parathyroid carcinoma: a report of cases
Background: Primary hyperparathyroidism (PHPT) is one of the most common endocrine diseases. Parathyroid carcinoma, a rare entity, comprises a small percentage of patients with hyperparathyroidism and represents 0.005% of all cancers and 14 mg/dl) often with renal and bone involvement by the onset of presentation. Biochemical or ultrasonographic features (lesion size, very high serum calcium and parathyroid hormone levels) may predict aggressive disease, but this is not always the case.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Parathyroid carcinoma: a report of cases
Background: Primary hyperparathyroidism (PHPT) is one of the most common endocrine diseases. Parathyroid carcinoma, a rare entity, comprises a small percentage of patients with hyperparathyroidism and represents 0.005% of all cancers and 14 mg/dl) often with renal and bone involvement by the onset of presentation. Biochemical or ultrasonographic features (lesion size, very high serum calcium and parathyroid hormone levels) may predict aggressive disease, but this is not always the case.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Breast cancer and family history for breast cancer in patients with differentiated thyroid carcinoma
Background and aim: The risk for breast cancer in patients with thyroid cancer has been investigated in previous studies, and has been found to be increased. In this study we, therefore present retrospective analysis of the patients with differentiated thyroid carcinoma in respect to breast cancer and family history for breast cancer. Methods: We conducted a retrospective study involving 455 patients with a diagnosis of differentiated thyroid carcinoma between January 2009 and March 2016. Results: The majority of them were female (403, 88.6%). Mean age at diagnosis was 45.5±12.8 (range 10–81) years. We detected that 0.7% patients with thyroid cancer had breast cancer and 13.4% patients had a family history of breast cancer within three generations of the proband. There was no significantly differences between family history of breast cancer and gender, age at diagnosis, pathologic types, and RAI therapy. Conclusion: In the literature, there are many clinical, epidemiological, and experimental studies that show an association between thyroid cancer and breast cancer. Our study is the first report showing history for breast cancer and family history for breast cancer is 0.7 and 13.4% this particular group of Turkish differentiated thyroid cancer patients.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Breast cancer and family history for breast cancer in patients with differentiated thyroid carcinoma
Background and aim: The risk for breast cancer in patients with thyroid cancer has been investigated in previous studies, and has been found to be increased. In this study we, therefore present retrospective analysis of the patients with differentiated thyroid carcinoma in respect to breast cancer and family history for breast cancer. Methods: We conducted a retrospective study involving 455 patients with a diagnosis of differentiated thyroid carcinoma between January 2009 and March 2016. Results: The majority of them were female (403, 88.6%). Mean age at diagnosis was 45.5±12.8 (range 10–81) years. We detected that 0.7% patients with thyroid cancer had breast cancer and 13.4% patients had a family history of breast cancer within three generations of the proband. There was no significantly differences between family history of breast cancer and gender, age at diagnosis, pathologic types, and RAI therapy. Conclusion: In the literature, there are many clinical, epidemiological, and experimental studies that show an association between thyroid cancer and breast cancer. Our study is the first report showing history for breast cancer and family history for breast cancer is 0.7 and 13.4% this particular group of Turkish differentiated thyroid cancer patients.
- Open Access
- 12 April 2017
- Published by MedCrave Group Kft. in MOJ Clinical & Medical Case Reports
- Vol. 6 (4) , 1-3
Inappropriate Treatment of Diabetes in an Adult Patient with Alström Syndrome: Effect of Adding Metformin
Alström syndrome (ALMS) is a rare autosomal recessive condition characterized by childhood onset cone-rod retinal dystrophy leading to juvenile blindness, neuronal hearing loss, obesity, insulin resistance (IR) and type 2 diabetes mellitus. Although the mean age of onset for diabetes is 15, diabetes can be diagnosed in these patients as early as age 5years. Younger patients rarely need insulin, but some patients require insulin in very high doses long term. Many respond to the treatment with insulinsensitizing agents such as metformin or thiazolidinediones (TZDs). A 22-year-old man with Alström syndrome, who does not respond well to insulin treatment, was admitted to our clinic. He was on regular insulin (330u/day). At admission, his fasting blood glucose (FPG) was 169mg/dL, HbA1c was 8.7%, fasting serum insulin was 88mIU/mL, c-peptide was 3.77ng/mL. He was started on Metformin 2550mg/day additional to the insulin regimen. Because of hypoglycemic episodes, insulin doses were gradually decreased and then stopped in one month. Treatment was continued only with metformin. 3months later, his FPG was 141mg/dL, and HbA1c was 7.7%. Insulin resistance with hyperinsulinemia and progression to type 2 diabetes mellitus are common in patients with Alström syndrome, and in this case, metformin proved effective and allowed cessation of insulin therapy.
- 12 April 2017
- Published by MedCrave Group Kft. in MOJ Clinical & Medical Case Reports
- Vol. 6 (4) , 1-3
Open AccessInappropriate Treatment of Diabetes in an Adult Patient with Alström Syndrome: Effect of Adding Metformin
Alström syndrome (ALMS) is a rare autosomal recessive condition characterized by childhood onset cone-rod retinal dystrophy leading to juvenile blindness, neuronal hearing loss, obesity, insulin resistance (IR) and type 2 diabetes mellitus. Although the mean age of onset for diabetes is 15, diabetes can be diagnosed in these patients as early as age 5years. Younger patients rarely need insulin, but some patients require insulin in very high doses long term. Many respond to the treatment with insulinsensitizing agents such as metformin or thiazolidinediones (TZDs). A 22-year-old man with Alström syndrome, who does not respond well to insulin treatment, was admitted to our clinic. He was on regular insulin (330u/day). At admission, his fasting blood glucose (FPG) was 169mg/dL, HbA1c was 8.7%, fasting serum insulin was 88mIU/mL, c-peptide was 3.77ng/mL. He was started on Metformin 2550mg/day additional to the insulin regimen. Because of hypoglycemic episodes, insulin doses were gradually decreased and then stopped in one month. Treatment was continued only with metformin. 3months later, his FPG was 141mg/dL, and HbA1c was 7.7%. Insulin resistance with hyperinsulinemia and progression to type 2 diabetes mellitus are common in patients with Alström syndrome, and in this case, metformin proved effective and allowed cessation of insulin therapy.
- 9 February 2016
- Vol. 41 (3) , 298-301
Serum heart type fatty acid binding protein levels are not changed in hyperthyroidism.
Heart type fatty acid binding protein (H-FABP) is a small protein and released into the circulation when myocardial damage has occurred. Previous studies have demonstrated that H-FABP is closely associated with cardiac and some endocrinologic disorders including prediabetes, metabolic syndrome, and acromegaly. Hyperthyroism is a well-known disorder associated with cardiovascular diseases. We aimed to investigate the effect of hyperthyrodism on H-FABP levels. Forty six patients with hyperthyroidism with no known history of coronary artery disease and 40 healthy controls are involved in the study. Serum H-FABP levels are measured using sandwich enzyme-linked immunosorbent assay. There was no significant difference between serum H-FABP levels of patients with hyperthyroidism and controls (871±66 pg/mL, and 816±66 pg/mL, respectively P=0.56). There was no significant correlation between H-FABP, free triiodothyronine (fT3), free thyroxine (fT4), and thyroid stimulating hormone (TSH) levels in patients and controls. Serum H-FABP levels are not altered in patients with hyperthyroidism.
- 9 February 2016
- Vol. 41 (3) , 298-301
Serum heart type fatty acid binding protein levels are not changed in hyperthyroidism.
Heart type fatty acid binding protein (H-FABP) is a small protein and released into the circulation when myocardial damage has occurred. Previous studies have demonstrated that H-FABP is closely associated with cardiac and some endocrinologic disorders including prediabetes, metabolic syndrome, and acromegaly. Hyperthyroism is a well-known disorder associated with cardiovascular diseases. We aimed to investigate the effect of hyperthyrodism on H-FABP levels. Forty six patients with hyperthyroidism with no known history of coronary artery disease and 40 healthy controls are involved in the study. Serum H-FABP levels are measured using sandwich enzyme-linked immunosorbent assay. There was no significant difference between serum H-FABP levels of patients with hyperthyroidism and controls (871±66 pg/mL, and 816±66 pg/mL, respectively P=0.56). There was no significant correlation between H-FABP, free triiodothyronine (fT3), free thyroxine (fT4), and thyroid stimulating hormone (TSH) levels in patients and controls. Serum H-FABP levels are not altered in patients with hyperthyroidism.
- Open Access
- 1 June 2015
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 59 (3) , 270-272
Transformation of nonfunctioning pancreatic tumor into malignant insulinoma after 3 years: an uncommon clinical course of insulinoma
A 62-year-old man admitted to our outpatient clinic with two months of recurrent life threatening hypoglycemia episodes. He was diagnosed as malignant insulinoma with multiple metastases of liver and peripancreatic lymph nodes. Liver biopsy specimen was demonstrated grade 2 neuroendocrine tumor compatible with clinical and radiological results. He was followed under the treatment of continuous intravenous glucose infusion during the diagnostic procedures. He had a pancreatic lesion history measured 20 x 12 mm in diameter via the abdominal tomography examination approximately two years before the diagnosis. Unusual course of this case suggests the transformation of nonfunctioning pancreatic neuroendocrine tumor into functional insulin secreting tumor with metastases. The patient was found inoperable and started on chemotherapy. Arch Endocrinol Metab. 2015;59(3):270-2
- 1 June 2015
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 59 (3) , 270-272
Open AccessTransformation of nonfunctioning pancreatic tumor into malignant insulinoma after 3 years: an uncommon clinical course of insulinoma
A 62-year-old man admitted to our outpatient clinic with two months of recurrent life threatening hypoglycemia episodes. He was diagnosed as malignant insulinoma with multiple metastases of liver and peripancreatic lymph nodes. Liver biopsy specimen was demonstrated grade 2 neuroendocrine tumor compatible with clinical and radiological results. He was followed under the treatment of continuous intravenous glucose infusion during the diagnostic procedures. He had a pancreatic lesion history measured 20 x 12 mm in diameter via the abdominal tomography examination approximately two years before the diagnosis. Unusual course of this case suggests the transformation of nonfunctioning pancreatic neuroendocrine tumor into functional insulin secreting tumor with metastases. The patient was found inoperable and started on chemotherapy. Arch Endocrinol Metab. 2015;59(3):270-2
- Open Access
- 1 November 2014
- Published by FapUNIFESP (SciELO) in Archives of Endocrinology and Metabolism
- Vol. 58 (8) , 851-854
Papillary thyroid cancer case masked by subacute thyroiditis
Subacute thyroiditis (SAT) association with thyroid carcinoma has been rarely reported in the literature. We present a patient with SAT and papillary thyroid cancer that was suspected by ultrasonographic evaluation (US) following SAT treatment. A fifty-four-year old female patient referred to our department due to tachycardia, jitteriness and pain in cervical region for the past one month. SAT diagnosis was established by physical examination, laboratory and ultrasonographic findings. After treatment, control thyroid US revealed regression of the hypoechogenic regions seen in both lobes, and a previously unreported hypoechogenic lesion with microcalcification focus that had irregular borders and was not clearly separated from the surrounding parenchyma located in the posterior aspect of the lobe (Elasto score: 4, Strain index: 7.08). Fine needle aspiration biopsy was taken from this nodule; cytology was assessed to be compatible with papillary thyroid carcinoma. Postsurgical pathology evaluation showed a papillary microcarcinoma. SAT may produce ultrasound changes that obscure the coexistence of papillary carcinoma. We recommend that patients with SAT have ultrasonography after they recover. Hypoechogenic regions bigger than 1 cm that are present in the follow-up post-therapy US should be assessed by biopsy.
- 1 November 2014
- Published by FapUNIFESP (SciELO) in Archives of Endocrinology and Metabolism
- Vol. 58 (8) , 851-854
Open AccessPapillary thyroid cancer case masked by subacute thyroiditis
Subacute thyroiditis (SAT) association with thyroid carcinoma has been rarely reported in the literature. We present a patient with SAT and papillary thyroid cancer that was suspected by ultrasonographic evaluation (US) following SAT treatment. A fifty-four-year old female patient referred to our department due to tachycardia, jitteriness and pain in cervical region for the past one month. SAT diagnosis was established by physical examination, laboratory and ultrasonographic findings. After treatment, control thyroid US revealed regression of the hypoechogenic regions seen in both lobes, and a previously unreported hypoechogenic lesion with microcalcification focus that had irregular borders and was not clearly separated from the surrounding parenchyma located in the posterior aspect of the lobe (Elasto score: 4, Strain index: 7.08). Fine needle aspiration biopsy was taken from this nodule; cytology was assessed to be compatible with papillary thyroid carcinoma. Postsurgical pathology evaluation showed a papillary microcarcinoma. SAT may produce ultrasound changes that obscure the coexistence of papillary carcinoma. We recommend that patients with SAT have ultrasonography after they recover. Hypoechogenic regions bigger than 1 cm that are present in the follow-up post-therapy US should be assessed by biopsy.
- 17 April 2014
- Published by Bioscientifica in Endocrine Abstracts
Ghrelin may have a role in obesity pathogenesis in patients with vitamin D deficiency
Aim: Several studies suggest a link between vitamin D and obesity. Vitamin D may play a role in obesity. Ghrelin is an orexigenic peptide which induces obesity by central and peripheral mechanisms. Administration of ghrelin promotes food intake and decreased fat utilisation in rodents. Ghrelin levels are decreased in obese individuals.The aim of this study was to evaluate the relationship between vitamin D status and ghrelin levels. Methods: All subjects applying to our clinic between December 2011 and February 2012 for whom 25 OH vitamin D3 (25(OH)D) levels measured were enrolled to this cross-sectional study. Those with a history of any metabolic disorder and those of any form of medication effect on obesity and vitamin D status were excluded. Patients were classified into two groups based on levels of 25(OH)D as group 1 (25(OH)D n=65, and group 2 (25(OH)D ≥20 ng/ml, n=30. Results: A total of 95 patients mean aged 35.06 (range, 18–57) years were enrolled in the study. Age and sex were similar between groups (P>0.05). BMI and waist circumference were found significantly higher in patients with group 1 than group 2 (PP=0.05). Also ghrelin levels were significantly higher in patients with group 1 than group 2 (Pr=−0.262, P=0.01 r=0.253, P=0.03). However, a similar correlation was not found for the other metabolic parameters. Conclusion: Vitamin D deficiency effects the ghrelin levels and ghrelin might contribute to the pathogenesis of weight gain and obesity in vitamin D deficient individuals. Further prospective clinical studies are needed to establish the relationship between ghrelin and vitamin D to clarify the pathogenesis of human obesity.
- 17 April 2014
- Published by Bioscientifica in Endocrine Abstracts
Ghrelin may have a role in obesity pathogenesis in patients with vitamin D deficiency
Aim: Several studies suggest a link between vitamin D and obesity. Vitamin D may play a role in obesity. Ghrelin is an orexigenic peptide which induces obesity by central and peripheral mechanisms. Administration of ghrelin promotes food intake and decreased fat utilisation in rodents. Ghrelin levels are decreased in obese individuals.The aim of this study was to evaluate the relationship between vitamin D status and ghrelin levels. Methods: All subjects applying to our clinic between December 2011 and February 2012 for whom 25 OH vitamin D3 (25(OH)D) levels measured were enrolled to this cross-sectional study. Those with a history of any metabolic disorder and those of any form of medication effect on obesity and vitamin D status were excluded. Patients were classified into two groups based on levels of 25(OH)D as group 1 (25(OH)D n=65, and group 2 (25(OH)D ≥20 ng/ml, n=30. Results: A total of 95 patients mean aged 35.06 (range, 18–57) years were enrolled in the study. Age and sex were similar between groups (P>0.05). BMI and waist circumference were found significantly higher in patients with group 1 than group 2 (PP=0.05). Also ghrelin levels were significantly higher in patients with group 1 than group 2 (Pr=−0.262, P=0.01 r=0.253, P=0.03). However, a similar correlation was not found for the other metabolic parameters. Conclusion: Vitamin D deficiency effects the ghrelin levels and ghrelin might contribute to the pathogenesis of weight gain and obesity in vitamin D deficient individuals. Further prospective clinical studies are needed to establish the relationship between ghrelin and vitamin D to clarify the pathogenesis of human obesity.
- 17 April 2014
- Published by Bioscientifica in Endocrine Abstracts
Assessment of atrial electromechanical delay in patients with acromegaly
Aim: Cardiac rhythm abnormalities have been documented in acromegalic patients. Our aim is to evaluate atrial electromechanical delay (EMD) with tissue doppler imaging (TDI) in patients with acromegaly. Material and methods: Fourty patients with acromegaly (13 patients with remission disease and 27 patients with active disease; 22 women and 18 men; mean aged 46.1±10.3 years), and 37 age- and sex-matched healthy controls were enrolled in the study. Atrial conduction times of right atrium, left atrium and interatrial septum were measured by 2- dimensional TDI using a 3.5- MHz transducer (GE-Vingmed Ultrasound AS, Horten, Norway). Statistical analysis was performed on the basis of three groups; controls, active acromegaly (AA) and remission acromegaly (RA). Results: Left atrial conduction time was found as 61.54±13.13 ms in RA patients, 63.44±13.69 ms in AA patients, and 43.94±10.29 ms in controls (P=0.0001). Right atrial conduction time was not found as statistically significant (P>0.05) (RA patients; 11.92±3.84 ms, AA patients; 12.61±4.49 ms and controls 12.12±3.96 ms). Interatrial conduction time was found as 31.53±8.0 ms for RA, 35.65±8.96 ms for AA patients, and 22.79±6.89 ms for controls (P=0.0001). There was not statistically significant difference in left atrial, right atrial and interatrial conduction times between RA and AA groups (P>0.05). However, there was significant delay in left atrial and interatrial septum conduction time between both patients group and controls (RA vs controls, P=0.0001 and AA vs controls, P=0.0001 for left atrial conduction time; RA vs controls, P=0.003 and AA vs controls, P=0.0001, for interatrial septum conduction time) Conclusion: This study suggests that atrial conduction time is delayed in patients with acromegaly both in remission and active state. Atrial electromechanical delay can be a predisposition factor for increased arrhythmia in acromegalic patients. This must be evaluated with further studies.
- 17 April 2014
- Published by Bioscientifica in Endocrine Abstracts
Assessment of atrial electromechanical delay in patients with acromegaly
Aim: Cardiac rhythm abnormalities have been documented in acromegalic patients. Our aim is to evaluate atrial electromechanical delay (EMD) with tissue doppler imaging (TDI) in patients with acromegaly. Material and methods: Fourty patients with acromegaly (13 patients with remission disease and 27 patients with active disease; 22 women and 18 men; mean aged 46.1±10.3 years), and 37 age- and sex-matched healthy controls were enrolled in the study. Atrial conduction times of right atrium, left atrium and interatrial septum were measured by 2- dimensional TDI using a 3.5- MHz transducer (GE-Vingmed Ultrasound AS, Horten, Norway). Statistical analysis was performed on the basis of three groups; controls, active acromegaly (AA) and remission acromegaly (RA). Results: Left atrial conduction time was found as 61.54±13.13 ms in RA patients, 63.44±13.69 ms in AA patients, and 43.94±10.29 ms in controls (P=0.0001). Right atrial conduction time was not found as statistically significant (P>0.05) (RA patients; 11.92±3.84 ms, AA patients; 12.61±4.49 ms and controls 12.12±3.96 ms). Interatrial conduction time was found as 31.53±8.0 ms for RA, 35.65±8.96 ms for AA patients, and 22.79±6.89 ms for controls (P=0.0001). There was not statistically significant difference in left atrial, right atrial and interatrial conduction times between RA and AA groups (P>0.05). However, there was significant delay in left atrial and interatrial septum conduction time between both patients group and controls (RA vs controls, P=0.0001 and AA vs controls, P=0.0001 for left atrial conduction time; RA vs controls, P=0.003 and AA vs controls, P=0.0001, for interatrial septum conduction time) Conclusion: This study suggests that atrial conduction time is delayed in patients with acromegaly both in remission and active state. Atrial electromechanical delay can be a predisposition factor for increased arrhythmia in acromegalic patients. This must be evaluated with further studies.